These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 34169667)

  • 81. Comparison of Conventional, Diffusion, and Perfusion MRI Between Low-Grade and Anaplastic Extraventricular Ependymoma.
    Xing Z; Zhou X; Xiao Z; She D; Wang X; Cao D
    AJR Am J Roentgenol; 2020 Oct; 215(4):978-984. PubMed ID: 32809860
    [No Abstract]   [Full Text] [Related]  

  • 82. Posttreatment DSC-MRI is Predictive of Early Treatment Failure in Children with Supratentorial High-Grade Glioma Treated with Erlotinib.
    Lucas JT; Knapp BJ; Uh J; Hua CH; Merchant TE; Hwang SN; Patay Z; Broniscer A
    Clin Neuroradiol; 2018 Sep; 28(3):393-400. PubMed ID: 28382379
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Pseudoprogression in high-grade glioma.
    Knudsen-Baas KM; Moen G; Fluge Ø; Storstein A
    Acta Neurol Scand Suppl; 2013; (196):31-7. PubMed ID: 23190289
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Discriminating pseudoprogression and true progression in diffuse infiltrating glioma using multi-parametric MRI data through deep learning.
    Lee J; Wang N; Turk S; Mohammed S; Lobo R; Kim J; Liao E; Camelo-Piragua S; Kim M; Junck L; Bapuraj J; Srinivasan A; Rao A
    Sci Rep; 2020 Nov; 10(1):20331. PubMed ID: 33230285
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T.
    Grabner G; Nöbauer I; Elandt K; Kronnerwetter C; Woehrer A; Marosi C; Prayer D; Trattnig S; Preusser M
    Magn Reson Imaging; 2012 Jan; 30(1):139-47. PubMed ID: 21982163
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Comparison of Different Post-Processing Algorithms for Dynamic Susceptibility Contrast Perfusion Imaging of Cerebral Gliomas.
    Kudo K; Uwano I; Hirai T; Murakami R; Nakamura H; Fujima N; Yamashita F; Goodwin J; Higuchi S; Sasaki M
    Magn Reson Med Sci; 2017 Apr; 16(2):129-136. PubMed ID: 27646457
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Perfusion MRI (dynamic susceptibility contrast imaging) with different measurement approaches for the evaluation of blood flow and blood volume in human gliomas.
    Thomsen H; Steffensen E; Larsson EM
    Acta Radiol; 2012 Feb; 53(1):95-101. PubMed ID: 22114021
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Multiparametric 3T MR approach to the assessment of cerebral gliomas: tumor extent and malignancy.
    Di Costanzo A; Scarabino T; Trojsi F; Giannatempo GM; Popolizio T; Catapano D; Bonavita S; Maggialetti N; Tosetti M; Salvolini U; d'Angelo VA; Tedeschi G
    Neuroradiology; 2006 Sep; 48(9):622-31. PubMed ID: 16752135
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Quantitative vs. semiquantitative assessment of intratumoral susceptibility signals in patients with different grades of glioma.
    Bhattacharjee R; Gupta RK; Patir R; Vaishya S; Ahlawat S; Singh A
    J Magn Reson Imaging; 2020 Jan; 51(1):225-233. PubMed ID: 31087724
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Penumbra quantification from MR SWI-DWI mismatch and its comparison with MR ASL PWI-DWI mismatch in patients with acute ischemic stroke.
    Bhattacharjee R; Gupta RK; Das B; Dixit VK; Gupta P; Singh A
    NMR Biomed; 2021 Jul; 34(7):e4526. PubMed ID: 33880799
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Optimal differentiation of high- and low-grade glioma and metastasis: a meta-analysis of perfusion, diffusion, and spectroscopy metrics.
    Usinskiene J; Ulyte A; Bjørnerud A; Venius J; Katsaros VK; Rynkeviciene R; Letautiene S; Norkus D; Suziedelis K; Rocka S; Usinskas A; Aleknavicius E
    Neuroradiology; 2016 Apr; 58(4):339-50. PubMed ID: 26767528
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Usefulness of diffusion/perfusion-weighted MRI in patients with non-enhancing supratentorial brain gliomas: a valuable tool to predict tumour grading?
    Fan GG; Deng QL; Wu ZH; Guo QY
    Br J Radiol; 2006 Aug; 79(944):652-8. PubMed ID: 16641420
    [TBL] [Abstract][Full Text] [Related]  

  • 93. MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas.
    Maia AC; Malheiros SM; da Rocha AJ; da Silva CJ; Gabbai AA; Ferraz FA; Stávale JN
    AJNR Am J Neuroradiol; 2005 Apr; 26(4):777-83. PubMed ID: 15814920
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Glioma grading capability: comparisons among parameters from dynamic contrast-enhanced MRI and ADC value on DWI.
    Choi HS; Kim AH; Ahn SS; Shin NY; Kim J; Lee SK
    Korean J Radiol; 2013; 14(3):487-92. PubMed ID: 23690718
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The use of sodium MRI in the diagnosis of an anaplastic astrocytoma during immunotherapy: a case report.
    De Leon-Benedetti L; Narayanan S; Lee VK; Panigrahy A; Boada F; Bhatia A
    Childs Nerv Syst; 2024 Mar; 40(3):965-967. PubMed ID: 37878058
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A case report of targeted therapy with apatinib in a patient with recurrent high grade glioma.
    Ding X; Sun J; Fan T; Li B
    Medicine (Baltimore); 2018 Jun; 97(22):e10859. PubMed ID: 29851800
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Pseudoprogression of brain tumors.
    Thust SC; van den Bent MJ; Smits M
    J Magn Reson Imaging; 2018 May; 48(3):571-89. PubMed ID: 29734497
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Regorafenib in Glioblastoma Recurrence: How to Deal With MR Imaging Treatments Changes.
    Gaudino S; Marziali G; Giordano C; Gigli R; Varcasia G; Magnani F; Chiesa S; Balducci M; Costantini AM; Della Pepa GM; Olivi A; Russo R; Colosimo C
    Front Radiol; 2021; 1():790456. PubMed ID: 37492166
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Advanced MRI Protocols to Discriminate Glioma From Treatment Effects: State of the Art and Future Directions.
    Malik DG; Rath TJ; Urcuyo Acevedo JC; Canoll PD; Swanson KR; Boxerman JL; Quarles CC; Schmainda KM; Burns TC; Hu LS
    Front Radiol; 2022; 2():809373. PubMed ID: 37492687
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Progression versus pseudoprogression: radiological differentiation with contrast clearance analysis on brain MRI.
    Sheehan JP; Lee CC; Fadul CE
    J Neurooncol; 2024 Sep; 169(3):695-696. PubMed ID: 39042301
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.